Results 21 to 30 of about 15,824 (192)
Antibiotics, 2021 An increasing number of untreatable infections are recorded every year. Many studies have focused their efforts on developing new β-lactamase inhibitors to treat multi-drug resistant (MDR) isolates. In the present study, sulbactam/avibactam and sulbactam/
Fernando Pasteran +13 more
doaj +1 more source
Microbiology Spectrum, 2023 Klebsiella pneumoniae AR 0047 from the CDC and FDA Antibiotic Resistance Isolate Bank is resistant to cefiderocol, a siderophore-conjugated cephalosporin.
Sun Hee Moon, En Huang
doaj +1 more source
Effect of β-lactamase inhibitors on in vitro activity of β-lactam antibiotics against Burkholderia cepacia complex species [PDF]
, 2016 Background: Bacteria belonging to the Burkholderia cepacia complex (Bcc) are an important cause of chronic respiratory tract infections in cystic fibrosis patients. Intrinsic resistance to a wide range of antimicrobial agents, including a variety of beta-
Coenye, Tom, Everaert, Annelien
core +2 more sources
Frontiers in Pharmacology, 2021 Objective: To systematically review and compare the efficacy and posttreatment resistance of ceftazidime-avibactam therapy and ceftazidime-avibactam-based combination therapy in patients with Gram-negative pathogens.Methods: PubMed, Embase, Web of ...
Dan Li +8 more
doaj +1 more source
Multi-drug resistant Gram-negative bacteria: antibiotic-resistance and new treatment strategies [PDF]
, 2017 In this editorial, we treat the multi-drug-resistance of microorganisms such as Klebsiella pneumonia (Kp) and Acinetobacter baumanii and the issues concerning the management of these infections.
Angelis, Massimiliano De +2 more
core +1 more source
Microbiology Spectrum, 2022 The evolution of bacterial antibiotic resistance is exhausting the list of currently used antibiotics and endangers those in the pipeline. The combination of antibiotics is a promising strategy that may suppress resistance development and/or achieve ...
Congjuan Xu +7 more
doaj +1 more source
Pharmacokinetics of Non-β-Lactam β-Lactamase Inhibitors
Antibiotics, 2021 The growing emergence of drug-resistant bacterial strains is an issue to treat severe infections, and many efforts have identified new pharmacological agents.
Giacomo Luci +3 more
doaj +1 more source
A randomised, double-blind, phase 3 study comparing the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem for complicated intra-abdominal infections in hospitalised adults in Asia [PDF]
, 2017 Ceftazidime/avibactam comprises the broad-spectrum cephalosporin ceftazidime and the non-β-lactam β-lactamase inhibitor avibactam. This phase 3, randomised, double-blind study (NCT01726023) assessed the efficacy and safety of ceftazidime/avibactam plus ...
Chen, Q. +9 more
core +1 more source
The Surgical Infection Society revised guidelines on the management of intra-abdominal infection [PDF]
, 2017 Background: Previous evidence-based guidelines on the management of intra-abdominal infection (IAI) were published by the Surgical Infection Society (SIS) in 1992, 2002, and 2010. At the time the most recent guideline was released, the plan was to update
Chang, Phillip K +11 more
core +3 more sources
Inhibition of Klebsiella β-Lactamases (SHV-1 and KPC-2) by Avibactam: A Structural Study. [PDF]
PLoS ONE, 2015 β-Lactamase inhibition is an important clinical strategy in overcoming β-lactamase-mediated resistance to β-lactam antibiotics in Gram negative bacteria.
Nikhil P Krishnan +4 more
doaj +1 more source